Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 31;13(11):1536.
doi: 10.3390/brainsci13111536.

Advances in Glioblastoma Therapy: An Update on Current Approaches

Affiliations
Review

Advances in Glioblastoma Therapy: An Update on Current Approaches

Ramcharan Singh Angom et al. Brain Sci. .

Abstract

Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high grade of malignancy and an extremely unfavorable prognosis. The current efficacy of established treatments for GBM is insufficient, necessitating the prompt development of novel therapeutic approaches. The progress made in the fundamental scientific understanding of GBM is swiftly translated into more advanced stages of therapeutic studies. Despite extensive efforts to identify new therapeutic approaches, GBM exhibits a high mortality rate. The current efficacy of treatments for GBM patients is insufficient due to factors such as tumor heterogeneity, the blood-brain barrier, glioma stem cells, drug efflux pumps, and DNA damage repair mechanisms. Considering this, pharmacological cocktail therapy has demonstrated a growing efficacy in addressing these challenges. Towards this, various forms of immunotherapy, including the immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have emerged as potential strategies for enhancing the prognosis of GBM. Current investigations are focused on exploring combination therapies to mitigate undesirable side effects and enhance immune responses against tumors. Furthermore, clinical trials are underway to evaluate the efficacy of several strategies to circumvent the blood-brain barrier (BBB) to achieve targeted delivery in patients suffering from recurrent GBM. In this review, we have described the biological and molecular targets for GBM therapy, pharmacologic therapy status, prominent resistance mechanisms, and new treatment approaches. We also discuss these promising therapeutic approaches to assess prospective innovative therapeutic agents and evaluated the present state of preclinical and clinical studies in GBM treatment. Overall, this review attempts to provide comprehensive information on the current status of GBM therapy.

Keywords: glioblastoma multiforme; immunotherapy; nanocarriers; radiation; surgery; therapy; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Shergalis A., Bankhead A., 3rd, Luesakul U., Muangsin N., Neamati N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol. Rev. 2018;70:412–445. doi: 10.1124/pr.117.014944. - DOI - PMC - PubMed
    1. Wu W., Klockow J.L., Zhang M., Lafortune F., Chang E., Jin L., Wu Y., Daldrup-Link H.E. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol. Res. 2021;171:105780. doi: 10.1016/j.phrs.2021.105780. - DOI - PMC - PubMed
    1. Mehta M., Wen P., Nishikawa R., Reardon D., Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit. Rev. Oncol. Hematol. 2017;111:60–65. doi: 10.1016/j.critrevonc.2017.01.005. - DOI - PubMed
    1. Becker A.P., Sells B.E., Haque S.J., Chakravarti A. Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology. Cancers. 2021;13:761. doi: 10.3390/cancers13040761. - DOI - PMC - PubMed
    1. Eisenbarth D., Wang Y.A. Glioblastoma heterogeneity at single cell resolution. Oncogene. 2023;42:2155–2165. doi: 10.1038/s41388-023-02738-y. - DOI - PMC - PubMed

LinkOut - more resources